Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells()

Combination therapy has been regarded as a potent strategy to overcome multidrug resistance (MDR). In this study, we adopt Adjudin (ADD), a mitochondria inhibitor, and Doxorubicin (DOX), a common chemo-drug, to treat drug-resistant cancer cells (MCF-7/ADR) in combination. Given the different physico...

Full description

Saved in:
Bibliographic Details
Published in:J Mater Chem B Mater Biol Med
Main Authors: Li, Xu, Gao, Cuixia, Wu, Yupei, Cheng, C-Yan, Xia, Weiliang, Zhang, Zhiping
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865403/
https://ncbi.nlm.nih.gov/pubmed/27182439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c4tb01764a
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items